Feedback / Questions
NP-160 - Breathtec Biomedical
http://globenewswire.com/news-release/2019/01/21/1702820/0/en/Nash-Pharmaceuticals-Announces-84-Reduction-of-Fibrosis-by-Additional-Lead-Compound-In-Second-Pre-Clinical-Study-For-Non-Alcoholic-Fatty-Liver-Disease.html
Jan 28, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next